Aethlon Medical (AEMD) EBIT (2010 - 2026)

Aethlon Medical's EBIT history runs 17 years deep, the most recent figure standing at -$1.9 million for Q1 2026.

• Quarterly EBIT rose 3.73% year-over-year to -$1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.3 million (up 21.92% YoY) and the FY2026 annual result came in at -$7.3 million, up 21.92% from the prior year.
• EBIT was -$1.9 million for Q1 2026 at Aethlon Medical, up from -$2.1 million in the prior quarter.
• Across five years, EBIT topped out at -$1.5 million in Q3 2025 and bottomed at -$3.8 million in Q1 2022.
• A 5-year average of -$2.6 million and a median of -$2.6 million in 2024 frame the typical range for EBIT.
• Annual changes were most pronounced in 2022 — EBIT slumped 82.46% — and 2024, when it jumped 49.13%.
• Aethlon Medical's EBIT stood at -$2.8 million in 2022, then dropped by 25.17% to -$3.6 million in 2023, then soared by 49.13% to -$1.8 million in 2024, then fell by 13.63% to -$2.1 million in 2025, then climbed by 6.44% to -$1.9 million in 2026.
• Business Quant data shows AEMD's EBIT at -$1.9 million in Q1 2026, -$2.1 million in Q4 2025, and -$1.5 million in Q3 2025.